Key Drivers
- Net Cash Strength
- Persistent Losses
- Negative Cash Flow
AIAI Summary
ANRO has evolved into a well-funded, multi-asset precision-psychiatry platform with several 2027 readouts, but its ~$1.15B valuation already assumes meaningful clinical validation; investors should wait for a stronger technical entry or accumulating evidence that its biomarker strategy can deliver clearly differentiated efficacy before underwriting upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net Cash Strength
- •Persistent Losses
- •Negative Cash Flow
ANRO offers strong net-cash liquidity and low leverage, but its lack of revenue, persistent losses, negative cash flow, and premium 5.2x book valuation make it a high-risk, future-prospects investment.
Price Behavior
Key Price Behavior Insights:
- •Accelerating decline
- •Oversold momentum
- •Key support test
ANRO is in a cautious downtrend over the last month, but an oversold RSI near 29 may support a bounce if $30.00 holds; reclaiming $31.68–$32.00 is needed for near-term improvement.
Decline accelerated after the $36.64 peak on 2026-09-02
Sentiment & News
Key News Insights:
- •Institutional Buying
- •Analyst Support
- •Investor Visibility
Alto Neuroscience gained momentum through new institutional buying, a 52-week high, mostly positive analyst ratings, and expanded executive and investor-outreach activity.
The developments are broadly supportive for Alto's near-term market sentiment and investor attention
Similar Companies in Healthcare
Other companies in the same sector with AI ratings